Martin Carroll
Martin Carroll
Associate Professor, University of Pennsylvania
Potvrđena adresa e-pošte na
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
Cancer Genome Atlas Research Network
New England Journal of Medicine 368 (22), 2059-2074, 2013
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate
PS Ward, J Patel, DR Wise, O Abdel-Wahab, BD Bennett, HA Coller, ...
Cancer cell 17 (3), 225-234, 2010
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
LP Vu, BF Pickering, Y Cheng, S Zaccara, D Nguyen, G Minuesa, T Chou, ...
Nature medicine 23 (11), 1369-1376, 2017
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
M Carroll, S Ohno-Jones, S Tamura, E Buchdunger, J Zimmermann, ...
Blood, The Journal of the American Society of Hematology 90 (12), 4947-4952, 1997
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
O Abdel-Wahab, M Adli, LM LaFave, J Gao, T Hricik, AH Shih, S Pandey, ...
Cancer cell 22 (2), 180-193, 2012
Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism
T Farge, E Saland, F De Toni, N Aroua, M Hosseini, R Perry, C Bosc, ...
Cancer discovery 7 (7), 716-735, 2017
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu, SE Simpson, TJ Scialla, A Bagg, M Carroll
Blood 102 (3), 972-980, 2003
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
ML Guzman, RM Rossi, S Neelakantan, X Li, CA Corbett, DC Hassane, ...
Blood, The Journal of the American Society of Hematology 110 (13), 4427-4435, 2007
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ...
Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice
JE Sarry, K Murphy, R Perry, PV Sanchez, A Secreto, C Keefer, ...
The Journal of clinical investigation 121 (1), 384-395, 2011
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
M Wunderlich, FS Chou, KA Link, B Mizukawa, RL Perry, M Carroll, ...
Leukemia 24 (10), 1785-1788, 2010
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ...
Leukemia 29 (8), 1637-1647, 2015
Distinct IL-2 receptor signaling pattern in CD4+ CD25+ regulatory T cells
SJ Bensinger, PT Walsh, J Zhang, M Carroll, R Parsons, JC Rathmell, ...
The Journal of Immunology 172 (9), 5287-5296, 2004
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
S Li, FE Garrett-Bakelman, SS Chung, MA Sanders, T Hricik, F Rapaport, ...
Nature medicine 22 (7), 792-799, 2016
The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase …
M Carroll, MH Tomasson, GF Barker, TR Golub, DG Gilliland
Proceedings of the National Academy of Sciences 93 (25), 14845-14850, 1996
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR
SM Ranuncolo, JM Polo, J Dierov, M Singer, T Kuo, J Greally, R Green, ...
Nature immunology 8 (7), 705-714, 2007
Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
CM McMahon, T Ferng, J Canaani, ES Wang, JJD Morrissette, ...
Cancer discovery 9 (8), 1050-1063, 2019
Single-cell mutation analysis of clonal evolution in myeloid malignancies
LA Miles, RL Bowman, TR Merlinsky, IS Csete, AT Ooi, ...
Nature 587 (7834), 477-482, 2020
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
EO Hexner, C Serdikoff, M Jan, CR Swider, C Robinson, S Yang, ...
Blood, The Journal of the American Society of Hematology 111 (12), 5663-5671, 2008
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
AP Im, AR Sehgal, MP Carroll, BD Smith, A Tefferi, DE Johnson, ...
Leukemia 28 (9), 1774-1783, 2014
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20